CLOs on the Move

Xilio Therapeutics

www.xiliotx.com

 
Xilio is a Waltham, Massachusetts-based biopharmaceutical company focused on defeating cancer. The company`s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.xiliotx.com
  • 828 Winter Street
    Waltham, MA USA 02451
  • Phone: 617.833.1027

Executives

Name Title Contact Details
Christopher Frankenfield
 General Counsel Profile

Similar Companies

Oxford Instruments PLC

Oxford Instruments PLC is a Carteret, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Veritas Clinical Specialties

Veritas Clinical Specialties is a Topeka, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MediQuest Therapeutics

MediQuest Therapeutics is a Maple Valley, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

deCODE genetics

deCODE genetics is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Revance

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.